NO20071322L - Human Growth Hormone Conjugates of Glycerol Branched Polyethylene Glycol, Process for its Preparation and Method for Use thereof - Google Patents
Human Growth Hormone Conjugates of Glycerol Branched Polyethylene Glycol, Process for its Preparation and Method for Use thereofInfo
- Publication number
- NO20071322L NO20071322L NO20071322A NO20071322A NO20071322L NO 20071322 L NO20071322 L NO 20071322L NO 20071322 A NO20071322 A NO 20071322A NO 20071322 A NO20071322 A NO 20071322A NO 20071322 L NO20071322 L NO 20071322L
- Authority
- NO
- Norway
- Prior art keywords
- growth hormone
- human growth
- preparation
- polyethylene glycol
- branched polyethylene
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 6
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 6
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title 3
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- 230000006320 pegylation Effects 0.000 abstract 2
- 206010012559 Developmental delay Diseases 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Det beskrives en PEGylering av menneskelig veksthormon (hGH) ved bruk av et glycerolforgrenet PEG. Det beskrives videre prosesser for PEGylering av hGH. I tillegg beskriver oppfinnelsen farmasøytiske preparater omfattende PEGylert hGH. En ytterligere utførelsesform er bruken av PEGylert hGH for behandling av vekst- og utviklingsforstyrrelser.A PEGylation of human growth hormone (hGH) is described using a glycerol-branched PEG. Further processes for PEGylation of hGH are described. In addition, the invention discloses pharmaceutical compositions comprising PEGylated hGH. A further embodiment is the use of PEGylated hGH for the treatment of growth and development disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60594504P | 2004-08-31 | 2004-08-31 | |
PCT/IB2005/002939 WO2006024953A2 (en) | 2004-08-31 | 2005-08-25 | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20071322L true NO20071322L (en) | 2007-05-29 |
Family
ID=35708806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071322A NO20071322L (en) | 2004-08-31 | 2007-03-09 | Human Growth Hormone Conjugates of Glycerol Branched Polyethylene Glycol, Process for its Preparation and Method for Use thereof |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1789092A2 (en) |
JP (1) | JP2008511610A (en) |
KR (1) | KR20070042567A (en) |
CN (1) | CN101010105A (en) |
AP (1) | AP2007003919A0 (en) |
AR (1) | AR050851A1 (en) |
AU (1) | AU2005278903A1 (en) |
BR (1) | BRPI0515118A (en) |
CA (1) | CA2577999A1 (en) |
CR (1) | CR8942A (en) |
EA (1) | EA200700380A1 (en) |
EC (1) | ECSP077281A (en) |
GT (1) | GT200500235A (en) |
IL (1) | IL181085A0 (en) |
MA (1) | MA28908B1 (en) |
MX (1) | MX2007002441A (en) |
NL (1) | NL1029828C2 (en) |
NO (1) | NO20071322L (en) |
PE (1) | PE20060654A1 (en) |
TN (1) | TNSN07078A1 (en) |
TW (1) | TW200621291A (en) |
UY (1) | UY29088A1 (en) |
WO (1) | WO2006024953A2 (en) |
ZA (1) | ZA200701802B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
BR9812267B1 (en) | 1997-07-14 | 2013-11-26 | Recombinant Growth Hormone. | |
EP1144613B2 (en) | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
MX2008014358A (en) * | 2006-05-12 | 2008-11-24 | Dong A Pharm Co Ltd | Polyethylene glycol-interferon alpha conjugate. |
JP2008069073A (en) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | Lactoferrin conjugate and its manufacturing method |
KR101079993B1 (en) | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | Polyethylene glycol-G-CSF conjugate |
CL2008002399A1 (en) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c. |
WO2010011096A2 (en) * | 2008-07-23 | 2010-01-28 | Hanmi Pharmaceutical Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
AU2009276458B2 (en) | 2008-07-31 | 2014-06-19 | Pharmaessentia Corp. | Peptide-polymer conjugates |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
PT2355853T (en) * | 2008-10-10 | 2017-03-15 | Polyactiva Pty Ltd | Biodegradable polymer - bioactive moiety conjugates |
SI2340271T1 (en) | 2008-10-10 | 2019-08-30 | Polyactiva Pty Ltd. | Polymer-bioactive agent conjugates |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
JP6086528B2 (en) | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Growth hormone with long-term in vivo efficacy |
CN101831067A (en) * | 2010-05-31 | 2010-09-15 | 王二新 | Polyethylene glycol ester conjugate and application thereof in medicine preparation |
EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
CN102367290B (en) * | 2011-04-26 | 2013-05-08 | 厦门赛诺邦格生物科技有限公司 | Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof |
WO2014110867A1 (en) * | 2013-01-17 | 2014-07-24 | 厦门赛诺邦格生物科技有限公司 | Monofunctional branched polyethyleneglycol and bio-related substance modified by same |
CN104877127B (en) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification |
SI3215193T1 (en) | 2014-11-06 | 2024-02-29 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
JP7227633B2 (en) * | 2017-12-29 | 2023-02-22 | エフ. ホフマン-ラ ロシュ エージー. | Methods for providing PEGylated protein compositions |
EP3731872B1 (en) | 2017-12-29 | 2021-11-24 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
JP7137625B2 (en) * | 2017-12-29 | 2022-09-14 | エフ.ホフマン-ラ ロシュ アーゲー | Methods for providing PEGylated protein compositions |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
JP3092531B2 (en) * | 1996-11-05 | 2000-09-25 | 日本油脂株式会社 | Method for producing imidyl succinate-substituted polyoxyalkylene derivative |
BR9812267B1 (en) * | 1997-07-14 | 2013-11-26 | Recombinant Growth Hormone. | |
JP3921781B2 (en) * | 1998-02-12 | 2007-05-30 | 日本油脂株式会社 | Carboxyl group-containing polyoxyalkylene compound |
EP1144613B2 (en) * | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
IL162031A0 (en) * | 2001-11-20 | 2005-11-20 | Pharmacia Corp | Chemically-modified human growth hormone conjugates |
AP2005003246A0 (en) * | 2002-09-09 | 2005-03-31 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals |
JP4412461B2 (en) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | Modified bio-related substance, production method thereof and intermediate |
WO2004060406A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
TR201907313T4 (en) * | 2003-05-23 | 2019-06-21 | Nektar Therapeutics | PEG derivatives containing two PEG chains. |
-
2005
- 2005-08-25 EA EA200700380A patent/EA200700380A1/en unknown
- 2005-08-25 CA CA002577999A patent/CA2577999A1/en not_active Abandoned
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/en active Pending
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/en unknown
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/en not_active IP Right Cessation
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/en unknown
- 2005-08-25 EP EP05784225A patent/EP1789092A2/en not_active Withdrawn
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/en active Application Filing
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/en not_active Application Discontinuation
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/en active Pending
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/en not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/en unknown
- 2005-08-29 UY UY29088A patent/UY29088A1/en not_active Application Discontinuation
- 2005-08-30 NL NL1029828A patent/NL1029828C2/en not_active IP Right Cessation
- 2005-08-30 TW TW094129583A patent/TW200621291A/en unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/en unknown
-
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/en not_active Application Discontinuation
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/en unknown
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/en unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/en unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/en unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ECSP077281A (en) | 2007-03-29 |
MX2007002441A (en) | 2007-05-04 |
IL181085A0 (en) | 2007-07-04 |
EA200700380A1 (en) | 2007-10-26 |
GT200500235A (en) | 2006-03-21 |
ZA200701802B (en) | 2008-08-27 |
NL1029828C2 (en) | 2006-10-20 |
NL1029828A1 (en) | 2006-03-01 |
WO2006024953A3 (en) | 2007-01-18 |
JP2008511610A (en) | 2008-04-17 |
CA2577999A1 (en) | 2006-03-09 |
KR20070042567A (en) | 2007-04-23 |
EP1789092A2 (en) | 2007-05-30 |
PE20060654A1 (en) | 2006-08-12 |
MA28908B1 (en) | 2007-10-01 |
BRPI0515118A (en) | 2008-07-01 |
CR8942A (en) | 2007-08-16 |
AP2007003919A0 (en) | 2007-02-28 |
AU2005278903A1 (en) | 2006-03-09 |
TW200621291A (en) | 2006-07-01 |
CN101010105A (en) | 2007-08-01 |
WO2006024953A2 (en) | 2006-03-09 |
AR050851A1 (en) | 2006-11-29 |
UY29088A1 (en) | 2006-03-31 |
TNSN07078A1 (en) | 2008-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071322L (en) | Human Growth Hormone Conjugates of Glycerol Branched Polyethylene Glycol, Process for its Preparation and Method for Use thereof | |
WO2006058539A3 (en) | Growth hormone secretagogue receptor 1a ligands | |
CY1119309T1 (en) | COOPERATIVE USE OF TOY (+) - 1,4-Dihydro-7 - [(3S, 4S) -3-Methoxy-4- (Methylamino) -1-Pyrrolidinyl] -4-oxo-1 (2-thiazolyl) -1, 8-Naphthyridine-3-carboxylic acid and cytochrome c (ARA-C) for the treatment of leukemia | |
ATE463239T1 (en) | METHOD FOR PRODUCING STERILE SUSPENSIONS OR LYOPHILISATES OF POORLY SOLUBLE BASIC PEPTIDE COMPLEXES, PHARMACEUTICAL FORMULATIONS CONTAINING THESE AND THEIR USE AS MEDICINAL PRODUCTS | |
NO20063926L (en) | N-terminal monopegylated human growth hormone conjugates, methods of preparation and use thereof | |
WO2006004959A3 (en) | Pegylated interferon alpha-1b | |
DK1079806T3 (en) | Preparations for the application of anti-inflammatory, in particular antiseptic agents and / or agents promoting the healing of wounds, to the upper respiratory tract and / or the ear | |
WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
RU2008145084A (en) | ANALOGUES OF FACTOR IX HAVING A LONG-TERM HALF-TIME IN VIVO | |
NO20060924L (en) | Composition of a VEGF antagonist and an anti-proliferative agent | |
YU75903A (en) | Thiohydantoins and use thereof for treating diabetes | |
CY1112257T1 (en) | METHODS FOR TREATMENT OF INFLAMMATORY DISEASES USING SPECIAL BATTERIES OF HUMAN VASCULAR-2 | |
DE602005021770D1 (en) | INDOLE-1-YL-ACETIC DERIVATIVES | |
DE60323090D1 (en) | 1H-IMIDAZOÄ4,5-CÜCHINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE-DEPENDENT DISEASES | |
CY1112376T1 (en) | 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists | |
WO2008082507A3 (en) | Pharmaceutical compositions and method for treating inflammation in cattle and other animals | |
DK1223990T3 (en) | Formulations of hyaluronic acid for delivery of osteogenic proteins | |
DK1450771T3 (en) | Pharmaceutical compositions for treating skin lesions and mucous membranes and methods and kits for their use | |
DK2229440T3 (en) | RECOMBINANT ELASTASE PROTEINS AND PROCEDURES FOR PRODUCING AND USING THEREOF | |
DE50211137D1 (en) | SIDE-CHAIN HALOGENATED AMINODICARBONE ACID DERIVATIVES AS A MEDICAMENT FOR TREATING HEART CIRCULAR DISEASES | |
NO20051261L (en) | Morphine-6-glukuronidsalt | |
DK1189627T3 (en) | Compositions containing soluble forms of HLA-G for the treatment of inflammatory pathological conditions in the skin | |
WO2003093419A3 (en) | Preventing secondary lymphedema with vegf-d dna | |
NO20024673L (en) | Controlled-release pharmaceutical composition for oral use containing midodrine and / or desglymidodrine | |
DK1596879T3 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |